Skip to main content
Log in

The authors reply

  • Correspondence
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Walker MD, Salek SS, Bayer AJ. A review of quality of life in Alzheimer’s disease. Part 1: issues in assessing disease impact. Pharmacoeconomics 1998; 14 (5): 499–530

    Article  PubMed  CAS  Google Scholar 

  2. Salek SS, Walker MD, Bayer AJ. A review of quality of life in Alzheimer’s disease. Part 2: issues in assessing drug effects. Pharmacoeconomics 1998; 14 (6): 613–27

    Article  PubMed  CAS  Google Scholar 

  3. Greer M, Monteban H. A review of quality of life in Alzheimer’s disease. Parts 1 and 2: issues in assessing disease impact and drug effects [letter]. Pharmacoeconomics 1999; 15 (6): 641

    Article  PubMed  CAS  Google Scholar 

  4. Doward LC. The development of the Alzheimer’s carers’ quality of life instrument (ACQLI) [abstract no. 88]. Qual Life Res 1997; 6: Suppl. 7–8: 639

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Salek, S.S., Walker, M.D. & Bayer, A.J. The authors reply. Pharmacoeconomics 16, 417–419 (1999). https://doi.org/10.2165/00019053-199916040-00010

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00019053-199916040-00010

Keywords

Navigation